Indication

In the female:

Ovulation induction in infertility due to anovulation or impaired follicle-ripening.

Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (ART).

Luteal phase support.

Threatened and habitual abortion

In the male:

Hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins).

Delayed puberty associated with insufficient gonadotropic pituitary function.

Cryptorchidism, (not due to anatomical obstruction)

Used to treat oligospermia


Dosage & Administration

After addition of the solvent to the freeze-dried substance, the reconstituted HCG™ solution should be slowly administered intramuscularly.

In the female:

Ovulation induction and preparation of follicles for puncture: Usually, one injection of 5000- 10000IU HCG™ to complete treatment with an FSH-containing preparation.

Luteal phase support: Two repeat injections of 2500 to 5000IU. Each may be given within nine days following ovulation or embryo transfer (for example on day 3, 6 and 9 after ovulation induction).

Threatened & habitual abortion:  5000IU HCG™ will be given as  deep intramuscular injection twice weekly from the time of diagnosis (all before the 7th week of gestation)

In the male:

Hypogonadotropic hypogonadism: 2500 to 5000 IU HCG™, two times per week. If the main complaint is sterility, additional doses of an FSH-containing (50IU FSH) are to be administered daily or two to three times a week. This treatment should be continued for at least three months before any improvement in spermatogenesis can be expected. During this treatment testosterone replacement therapy should be suspended. Once achieved, the improvement may in some cases be maintained by HCG™ alone.


Precautions

In pregnancies occurring after induction of ovulation with gonadotropic preparations, there is an increased risk of multiplets birth. Unwanted ovarianhyperstimulation: In patients treated for infertility due to anovulation or impaired follicular ripening, the prior administration of an FSH containing preparation may lead to unwanted ovarian hyperstimulation. Therefore ultrasonic assessment of follicular development and determinations nations of estrogen levels should be performed prior to FSH-treatment and at regular intervals during FSH-treatment. Estrogen levels may rise very rapidly, e.g. more than a daily doubling for two or three consecutive days, and possibly reach excessively high values. If this unwanted ovarian hyperstimulation occurs (i.e. not as part of a treatment preparing for IVF/ET or GIFT/ZIFT), the administration of the FSH-containing preparation should be discontinued immediately. In that case HCGâ„¢ must not be given, because the administration of an LH-active gonadotrophin at this stage may induce, in addition to multiple ovulations, the ovarian hyperstimulation syndrome. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhoea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by large ovarian cysts (prone to rupture), ascites, often hydrothorax and occasionally thromboembolic phenomena.


Product Details


Related Products

Medroxy

Medroxy Progesterone Acetate
Hormone

Leroxy

Levothyroxine Sodium
Hormone

Tibo

Tibolone
Hormone

Remens

Norethisterone
Hormone

Allynol

Allylestrenol
Hormone